Open original FDA record ↗Recall record
- FDA identifier
- Z-1801-2017
- Company in FDA record
- BioMerieux SA
- FDA classification date
- Mar 20, 2017
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Fulvestrant cross reacts with the VIDAS Estradiol II immunoassay and may cause falsely elevated estradiol results in patients treated with Fulvestrant.
Source facts
- Action
- bioMerieux sent an Important Product Safety Notice A Product Safety Notice to all affected customers on March accounts on March 17, 2017, informing them not to use VIDAS Estradiol II test to test estradiol level in patients under Fulvestrant therapy. The letter did not request return of any of the product, and requested that they return an acknowledgement form acknowledging receipt of the notice and that they have followed the instructions and implemented the actions in the field notice. Customers with questions were instructed to contact their bioMerieux Customers Service representative. For questions regarding this recall call 314-731-8805.
- Initiated
- 2017-03-17
- Root cause
- Device Design
- Terminated
- 2022-02-16
- Distribution
- Nationwide Distribution including AZ, CA, CO, FL, GA, IN, IA, LA, MI, MS, NY, NC, OH, OK, OR, PA, TX, WA
- Recall number
- Z-1801-2017
- Recall status
- Terminated
- CDRH record ID
- 154042
- FDA classified
- 2017-03-20
- Recall event number
- 76727